Indications for potassium citrate include:
1. Oxalic acid nephrolithiasis and partial uric acid nephrolithiasis. Prevent stone formation in patients with polycystic kidney disease. Prevent stone recurrence after ESWL or lithotomy;
2. Distal renal tubular acidosis complicated with hypercalciuria is more common in children.
3. Renal hypercalciuria and hyperoxaluria.
4. Acetazolamide prevents renal complications in the treatment of glaucoma.
5. Supplement potassium during hypertension treatment.
Potassium citrate is generally prohibited in the following cases:
1. Urinary tract infection.
2. Bird droppings and kidney stone disease.
3. Hyperkalemia and advanced chronic renal failure.
4. Peptic ulcer or gastritis.
5. Gastrointestinal bleeding.
6. Coagulation dysfunction and varicose veins of lower leg.
7. Metabolic alkalosis. Potassium citrate is considered very safe when used in therapeutic doses.
Even if recognized as a single dose day, the average daily dose will occupy 60-75% of the free renal potassium excretion capacity. Physiological and therapeutic citrate concentrations in urine far exceed other inhibitors. Except for mild transient metabolic alkalosis, the therapeutic dose will not cause any significant changes in any biochemical or endocrine parameters of the blood. A decrease in urinary calcium and an increase in calcium oxalate phosphate excretion were observed. In patients with hypocytosis, the response to citrate treatment dose was less. One year remission of stone disease was observed in 70-75% of cases.